Epstein-Barr virus peptide-major histocompatibility complex (EBV peptide-MHC) (EBV pMHC)

Epstein-Barr virus (EBV) peptide-major histocompatibility complexes (pMHC) are specialized molecular targets found on the surface of cells infected with EBV or in EBV-associated malignancies. These complexes consist of short peptides derived from viral latent proteins, such as Latent Membrane Proteins 1 and 2 (LMP1, LMP2) and Epstein-Barr Nuclear Antigen 1 (EBNA1), which are loaded onto Human Leukocyte Antigen (HLA) molecules (Young & Rickinson, 2004). In cancers like nasopharyngeal carcinoma and certain lymphomas, these pMHCs serve as highly specific neoantigens that distinguish malignant cells from healthy tissue (Taylor et al., 2015). Therapeutic strategies targeting these complexes include adoptive T-cell therapies, such as tabelecleucel, and engineered T-cell receptor (TCR-T) therapies designed to recognize specific peptide-HLA combinations (Prockop et al., 2022). Because these targets are viral in origin, they offer a favorable safety profile with minimal off-target expression in non-infected tissues (Smith et al., 2014). However, the efficacy of these treatments is restricted by the patient's HLA haplotype, requiring precise matching between the therapeutic agent and the host's MHC molecules (Lin et al., 2002). Additionally, tumors may attempt to evade immune detection by downregulating MHC expression or through other mechanisms of the immunosuppressive tumor microenvironment.

Other names

EBV-specific pMHCLMP1/LMP2/EBNA1-HLA complexesEBV-associated tumor-associated antigensEBV-latent antigen pMHC

Recognition of specific viral peptide-HLA complexes by T-cell receptors (TCRs) on cytotoxic T-lymphocytes, leading to targeted cell lysis via perforin and granzyme release (Smith et al., 2014).